Patten Group Inc. boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 71.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,480 shares of the life sciences company’s stock after purchasing an additional 615 shares during the quarter. Patten Group Inc.’s holdings in Illumina were worth $172,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Winslow Capital Management LLC acquired a new stake in shares of Illumina in the 2nd quarter worth $211,584,000. HPM Partners LLC increased its stake in shares of Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock worth $107,724,000 after acquiring an additional 749,424 shares during the last quarter. Fred Alger Management Inc. increased its stake in shares of Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after acquiring an additional 548,030 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after acquiring an additional 527,548 shares during the last quarter. Finally, Capital World Investors increased its stake in shares of Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after acquiring an additional 410,000 shares during the last quarter. 91.75% of the stock is owned by hedge funds and other institutional investors.

Illumina, Inc. (NASDAQ:ILMN) opened at $212.64 on Wednesday. Illumina, Inc. has a twelve month low of $124.75 and a twelve month high of $230.72. The company has a market capitalization of $31,260.06, a PE ratio of 62.60, a P/E/G ratio of 3.54 and a beta of 0.79. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period last year, the business posted $0.97 EPS. Illumina’s revenue for the quarter was up 17.6% on a year-over-year basis. equities analysts anticipate that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.

A number of analysts have issued reports on ILMN shares. Bank of America raised their target price on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Deutsche Bank raised Illumina from a “hold” rating to a “buy” rating and cut their price objective for the stock from $195.00 to $160.00 in a research report on Monday, October 23rd. Canaccord Genuity reissued a “buy” rating and set a $230.00 price objective (up from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $217.50 price objective for the company in a research report on Tuesday, September 19th. Finally, Argus raised their price objective on Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $201.98.

In related news, EVP Omead Ostadan sold 3,540 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $226.91, for a total transaction of $803,261.40. Following the completion of the transaction, the executive vice president now directly owns 26,827 shares in the company, valued at approximately $6,087,314.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $200.16, for a total value of $4,003,200.00. Following the transaction, the director now owns 539,176 shares of the company’s stock, valued at $107,921,468.16. The disclosure for this sale can be found here. Insiders have sold a total of 136,421 shares of company stock valued at $28,489,101 over the last 90 days. 0.89% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/12/13/patten-group-inc-purchases-615-shares-of-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related stocks with our FREE daily email newsletter.